Price
$64.63+11.55%Social Signal Score
Analyst Ratings
42 analysts52-week range
- Last close
- $64.63
- Off 52w high
- -1.9%
- 200-day average
- $56.71
- vs 200-day
- +14.0%
Revenue
$12.97B+163.57%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Christopher Boerner
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 32,500
- Beta
- 0.23
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 2.68
Financials
Revenue
$12.97B+163.6%Net Income
$3.32B+176.0%EBITDA
$4.94B+189.6%Free Cash Flow
$3.09B+190.5%EPS (diluted)
$1.62+125.0%Shares Outstanding (diluted)
2.05B+22.0%Operating Expenses
$4.79BCash & Debt
$11.07BReturn of Capital
$1.29BRevenue by Segment (annual)
$48.20BDividend per Share
$0.63Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $48.20B | $7.05B | $3.46 |
| 2024 | $48.30B | $-8.95B | $-4.41 |
| 2023 | $45.01B | $8.03B | $3.88 |
| 2022 | $46.16B | $6.33B | $2.97 |
| 2021 | $46.38B | $6.99B | $3.15 |
| 2020 | $42.52B | $-8.99B | $-3.98 |
| 2019 | $26.14B | $3.44B | $2.02 |
| 2018 | $22.56B | $4.92B | $3.03 |
| 2017 | $20.78B | $1.01B | $0.61 |
| 2016 | $19.43B | $4.46B | $2.67 |
| 2015 | $16.56B | $1.56B | $0.97 |
| 2014 | $15.88B | $2.00B | $1.21 |
| 2013 | $16.39B | $2.56B | $1.56 |
| 2012 | $17.62B | $1.96B | $1.17 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from BMY's reported EPS growth of 8.7% a year over 13 years.
- EPS in 5 years
- $5.24
- Implied price
- $83.92
- Return from $61.15
- 6.5% a year
To earn 15.0% a year on these assumptions you'd need to buy at $41.72 — -31.8% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 14 | 16 | 18 | 20 |
|---|---|---|---|---|---|
| -1.3% | -8.7% | -5.8% | -3.3% | -1.0% | 1.1% |
| 3.7% | -4.0% | -1.0% | 1.6% | 4.1% | 6.3% |
| 8.7% | 0.6% | 3.7% | 6.5% | 9.1% | 11.4% |
| 13.7% | 5.2% | 8.5% | 11.4% | 14.1% | 16.5% |
| 18.7% | 9.8% | 13.3% | 16.3% | 19.1% | 21.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
117+61.14%Social Signal Score
Mentions (57)
- Newszacks.com·21h ago·Neutral
BMY or ARGX: Which Is the Better Value Stock Right Now? Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Bristol Myers Squibb (BMY) or argenex SE (ARGX). But which of these two stocks presents investors with the better value opportunity right now?
View source ↗ - Newszacks.com·23h ago·Positive
Are Investors Undervaluing Bristol Myers Squibb (BMY) Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
View source ↗ - Newszacks.com·23h ago·Positive
3 Stocks With Broker Rating Upgrades Amid Resilient Equity Markets Dollar General, Bristol-Myers and Equinor stand out after broker rating upgrades, backed by projected earnings growth and resilient U.S. equity markets.
View source ↗ - News (Marketaux)insidermonkey.com·2d ago·Neutral
AbbVie (ABBV) vs Bristol Myers (BMY): Which is a Better Stock to Buy? (NYSE:ABBV) closed at $262.82 on October[+350 characters]
View source ↗ - Newsfool.com·3d ago·Positive
Bristol Myers Squibb Now Trades at Only 9.4X Forward Earnings -- Is This Value Stock a Buy? Bristol Myers has faced patent cliffs in recent years, and there are more on the horizon. The company seems relatively well equipped to deal with this issue moving forward.
View source ↗ - Newszacks.com·3d ago·Positive
Will Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio? Bristol Myers' Camzyos gains a broader FDA label and strong sales growth, while emerging competitors and pipeline setbacks shape its cardiovascular outlook.
View source ↗ - Newsfool.com·4d ago·Neutral
Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale Johnson & Johnson generates consistently higher quarterly revenue than Bristol-Myers Squibb, maintaining a clear lead in total dollars over the entire observed eight-quarter period without any interruption. Both companies experienced a gentle pattern of quarter-over-quarter revenue growth over the last two calendar years, though the exact quarterly figures occasionally fluctuated between consecutive reporting periods.
View source ↗ - Newsbusinesswire.com·5d ago·Negative
U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb's CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients* PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CAMZYOS--U.S. FDA Approves Expanded Indication for BMS's CAMZYOS for the Treatment of Symptomatic oHCM in Adults and Pediatric Patients.
View source ↗ - News247wallst.com·5d ago·Negative
Bristol Myers Squibb's Dividend Sustainability Hinges on One Critical Cash Flow Metric Bristol Myers Squibb has raised its dividend for 17 straight years, but a looming patent cliff on its biggest cash generator puts that streak on a collision course with reality in 2027.
View source ↗ - Newszacks.com·6d ago·Neutral
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
View source ↗ - Newsfool.com·7d ago·Negative
3 Numbers That Explain Bristol Myers Squibb's Dirt Cheap Valuation Bristol Myers Squibb's stock price is up 42.5% in the past 12 months, yet it still trades at a discounted valuation. Investors remain uncertain about the company's efforts to replace legacy drug sales with the sale of new drug products.
View source ↗ - Newsfool.com·8d ago·Positive
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? Bristol Myers Squibb's Growth Portfolio sales rose 15% in the second quarter, and management raised its 2026 revenue guidance to $49 billion to $50 billion. Novo Nordisk expects 2026 adjusted sales to range from flat to down 6% at constant exchange rates, even after raising that outlook in August.
View source ↗ - Newsseekingalpha.com·9d ago·Positive
Buy 5 Barron's Better Bets (Than T-Bills) Out Of 11 'Safer' September DiviDogs Long-term bond yields persist despite pressure and circular remedies. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge dividends. They should be a better bet than treasuries.” —Barron's Weekly reported in October 2024. It's still true more than ever as 10-yr bonds yield >5%. Interviewed by Barron's, Steven Wieti
View source ↗ - Newszacks.com·11d ago·Negative
Why Women-Run Companies Deserve a Place in Your Portfolio BMY, HALO, TGT, NEO and ROST stocks show how women-led companies are redefining growth with discipline, agility and results.
View source ↗ - Newszacks.com·11d ago·Negative
Can Recent Traction With Key Drugs and Pipeline Progress Boost BMY? Bristol Myers Squibbs' growth portfolio is gaining ground, with newer drugs offsetting mature-product declines and reshaping its revenue mix.
View source ↗ - Newszacks.com·12d ago·Positive
New Strong Buy Stocks for September 24th BMY, HRTG, RDVT, NMR and ECO have been added to the Zacks Rank #1 (Strong Buy) List on September 24th, 2026.
View source ↗ - Newszacks.com·12d ago·Positive
Best Income Stocks to Buy for September 24th ECO, NMR, BMY made it to the Zacks Rank #1 (Strong Buy) income stocks list on September 24th, 2026.
View source ↗ - News247wallst.com·13d ago·Negative
4 Elite Dividend Stocks Yielding Up to 6.14% With Diversified Pipelines That Protect Your Payout Patent cliffs have buried lesser pharma dividends, yet these four Big Pharma giants keep raising payouts despite losing blockbuster exclusivities worth billions.
View source ↗ - Newszacks.com·14d ago·Neutral
BMY vs GILD: Which Biotech Stock Looks More Attractive Now? Bristol Myers' growth portfolio and pipeline advances offer multiple ways to offset legacy-product erosion, while valuation and leverage remain key factors.
View source ↗ - Newszacks.com·14d ago·Positive
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newsfool.com·16d ago·Neutral
Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder Bristol Myers Squibb's stock is up more than 17% so far this year. The company could be acquired by AstraZeneca.
View source ↗ - Newszacks.com·17d ago·Positive
Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects? Bristol Myers' Sotyktu delivers durable PsA responses for two years, supporting its growth strategy as competition intensifies.
View source ↗ - Newszacks.com·17d ago·Neutral
BMY vs. ARGX: Which Stock Is the Better Value Option? Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Bristol Myers Squibb (BMY) and argenex SE (ARGX). But which of these two stocks presents investors with the better value opportunity right now?
View source ↗ - Newsbusinesswire.com·18d ago·Neutral
Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026 PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026.
View source ↗ - Newszacks.com·18d ago·Positive
Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know Bristol Myers Squibb (BMY) closed the most recent trading day at $62.84, moving 1.19% from the previous trading session.
View source ↗ - Newszacks.com·20d ago·Neutral
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
View source ↗ - Newsfool.com·22d ago·Positive
Should You Buy Bristol Myers Squibb Stock Right Now for the Yield Alone? Patent cliff concerns continue to weigh down Bristol Myers Squibb's stock. The pharmaceutical company's management is taking active steps to counter some longstanding headwinds.
View source ↗ - News (Marketaux)finance.yahoo.com·23d ago·Positive
How Much Do You Really Need Invested in Bristol Myers Squibb to Collect $10,000 a Year? Our analysts combed the entire stock mar[+254 characters]
View source ↗ - News247wallst.com·23d ago·Negative
How Much Do You Really Need Invested in Bristol Myers Squibb to Collect $10,000 a Year? The exercise is simple: how large a position in Bristol Myers Squibb (NYSE:BMY | BMY Price Prediction) do you need to throw off $10,000 a year in dividend income? Start with the income target and solve backward, using the live
View source ↗ - Newszacks.com·25d ago·Negative
Bristol Myers Squibb (BMY) Declines More Than Market: Some Information for Investors Bristol Myers Squibb (BMY) reached $63.75 at the closing of the latest trading day, reflecting a -1.02% change compared to its last close.
View source ↗ - Newszacks.com·25d ago·Positive
BMY Gains 19.4% Year to Date: Should You Buy, Sell or Hold the Stock? Bristol Myers growth brands and pipeline progress are boosting momentum, but generic pressure on its legacy portfolio warrants caution.
View source ↗ - Newszacks.com·26d ago·Neutral
Will The Recent Pipeline Progress Boost BMY's Portfolio Expansion? Bristol Myers Squibb's positive arlo-cel data in heavily pretreated multiple myeloma could strengthen its cell therapy pipeline.
View source ↗ - Newsseekingalpha.com·31d ago·Positive
Bristol Myers Squibb's Breakout Is Here: Portfolio Renewal Gaining Momentum Growth assets now comprise 58.2% of Bristol Myers Squibb Company's revenues, with the legacy portfolio also reporting a promising deceleration in top-line erosion cadence. The successful Opdivo/Qvantig conversion and the upcoming launches like iberdomide/mezigdomide target significant multiple myeloma market opportunities. The raised FY2026 guidance and productivity initiatives drive top-line/margin expansion, with the r
View source ↗ - Newszacks.com·31d ago·Neutral
Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today In the most recent trading session, Bristol Myers Squibb (BMY) closed at $66.82, indicating a -1.87% shift from the previous trading day.
View source ↗ - Newszacks.com·31d ago·Positive
Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook? Bristol Myers??? Camzyos delivers durable five-year benefits, rising sales and potential adolescent label expansion.
View source ↗ - Newszacks.com·31d ago·Positive
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newsseekingalpha.com·32d ago·Neutral
Bristol Myers Squibb: Still Cheap, Despite What The Chart Says Bristol Myers Squibb remains a Strong Buy, trading at a 51% discount to sector median with a compelling risk/reward profile. BMY's growth portfolio delivered 15% YoY revenue growth, offsetting headwinds from Opdivo's decline and upcoming Eliquis patent expiry. The company boasts a 3.7% forward dividend yield, robust margins, and accelerating bottom-line growth, supporting its defensive, income-generating appeal.
View source ↗ - Newsseekingalpha.com·32d ago·Positive
Bristol Myers Squibb: Buy The Growth Portfolio At A Value Price Bristol Myers Squibb remains undervalued, trading at a 9.8x forward P/E with a 3.7% yield. BMY's growth portfolio now drives nearly 60% of revenue, offsetting legacy drug declines and supporting 5% YoY total revenue growth. Management raised full-year adjusted EPS guidance, with robust Eliquis growth and a strong pipeline of over 10 potential new medicines.
View source ↗ - Newswsj.com·32d ago·Negative
Drugmakers quietly halted autoimmune drug trials because of deaths or problematic side effects, raising questions about disclosure around experimental research Trial freezes by Novartis and Bristol Myers have triggered a race to understand why a promising autoimmune treatment turned risky.
View source ↗ - Newsbusinesswire.com·37d ago·Positive
Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026 PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten).
View source ↗ - Newsfool.com·37d ago·Negative
Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors Bristol Myers Squibb's cardiovascular drug Eliquis is set to lose patent protection in 2028. The company is busy bringing out new drugs and developing more to offset the revenue it will lose.
View source ↗ - Newszacks.com·39d ago·Neutral
Can Camzyos' Growth Offset Bristol Myers' Patent Pressures? BMY's Camzyos gains momentum as an adolescent expansion nears an FDA decision, while rivals advance competing heart drugs.
View source ↗ - Newsreuters.com·41d ago·Negative
Bristol Myers ends blood cancer drug deal with cell therapy maker Cellares Bristol Myers Squibb has ended its partnership with cell therapy startup Cellares to expand the manufacturing of its personalized blood cancer therapy, a company spokesperson told Reuters on Tuesday.
View source ↗ - News (RSS)yahoo·45d ago·Neutral
Bristol-Myers Squibb (BMY) Bets $2.3 Billion on Texas While Eli Lilly (LLY) Wins in the UK
View source ↗ - Newszacks.com·45d ago·Positive
Can Eliquis Cushion Bristol Myers' Legacy Portfolio Erosion? BMY's legacy portfolio faces generic pressure, but stronger Eliquis sales prompt a brighter 2026 revenue outlook.
View source ↗ - Newszacks.com·45d ago·Positive
Here's Why Bristol Myers Squibb (BMY) is a Strong Momentum Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗ - Newszacks.com·47d ago·Positive
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newszacks.com·52d ago·Neutral
Can BMY's First CELMoD Approval Support Its Growth Strategy? Bristol Myers wins FDA accelerated approval for Zenbexus, the first CELMoD therapy, as data show it doubles MRD-negative complete response rates.
View source ↗ - Newsbusinesswire.com·53d ago·Neutral
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CELMoD--U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS.
View source ↗ - Newsreuters.com·53d ago·Neutral
US FDA approves Bristol Myers' blood cancer treatment The U.S. FDA on Thursday approved Bristol Myers Squibb's combination treatment for patients with a rare form of blood cancer whose illness had relapsed or not responded to other treatments, the health regulator said.
View source ↗ - Newsreuters.com·53d ago·Negative
Lawsuit against Bristol Myers over delayed cancer drug is revived A U.S. federal appeals court said a judge erred in dismissing a $6.7 billion lawsuit accusing Bristol Myers Squibb of cheating former Celgene shareholders by delaying federal approval for three drugs, including the cancer treatment Breyanzi.
View source ↗ - Newszacks.com·54d ago·Negative
Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines? Bristol Myers growth portfolio now accounts for 56% of revenues, led by key drugs, including Opdivo Qvantig, Reblozyl and Breyanzi, helping offset generic erosion.
View source ↗ - News (Marketaux)insidermonkey.com·56d ago·Positive
Jim Cramer Highlights Pharmaceutical Giants as Non-Tech Innovation Plays Like JNJ and LLY Bristol-Myers Squi[+255 characters]
View source ↗ - Newszacks.com·56d ago·Positive
BMY Rallies 16.2% in Three Months: Buy, Sell or Hold the Stock? Bristol Myers Squibb's Growth Portfolio and pipeline support momentum, but generic headwinds and recent gains call for a cautious stance.
View source ↗ - Newsreuters.com·57d ago·Negative
Bristol Myers to build $2.3 billion manufacturing site in Houston Drugmaker Bristol Myers Squibb on Monday said it will spend about $2.3 billion to build a new manufacturing facility in Houston, Texas, part of a previously announced $40 billion commitment to invest in the United States.
View source ↗ - Newsbusinesswire.com·57d ago·Neutral
Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas.
View source ↗ - News (Alpha Vantage)Bloomberg·64d ago·Positive
Watch Tyson Falls on 3Q Results; Bristol-Myers Squibb Surges on Potential Acquisition | Stock Movers Bristol-Myers Squibb (SQB) shares surged due to news of a potential acquisition by AstraZeneca (AZN), whose shares dropped. Tyson (TSN) shares fell after reporting a 3Q sales shortfall, particularly in beef, and cutting full-year profit forecasts. SpaceX (SPCX) investors are preparing for the company's first earnings report as a public entity.
View source ↗
Earnings
Thu, Oct 29(in 3 weeks)
Consensus estimate $1.68 per share
Typical surprise +13.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$2.04 vs $1.60beat
- Thu, Apr 30$1.58 vs $1.42beat
- Thu, Feb 5$1.26 vs $1.23beat
- Thu, Oct 30$1.63 vs $1.52beat
- Thu, Jul 31$1.46 vs $1.09beat
- Thu, Apr 24$1.80 vs $1.49beat
Estimates and results for BMY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BMY officers and directors.
- Bought
- —
- Sold
- $2.3m
0 trades
4 trades
- Massacesi Cristiansold
- Holzer Phil Msold
- Elkins David Vsold
- Elkins David Vsold
96 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Thomas Hawley Tubervillesenate · AL · disclosed Aug 5, 2026 (477d later)Sell$1,001 - $15,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Buy$1,001 - $15,000
- Mike Kellyhouse · PA16 · disclosed Jun 12, 2026 (36d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (12d later)Sell$15,001 - $50,000
- Julie Johnsonhouse · TX32 · disclosed Jan 16, 2026 (29d later)Sell$1,001 - $15,000
- Julia Letlowhouse · LA05 · disclosed Jan 13, 2026 (447d later)Buy$1,001 - $15,000
- Julia Letlowhouse · LA05 · disclosed Jan 13, 2026 (260d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jan 12, 2026 (24d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Dec 15, 2025 (33d later)Buy$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Dec 12, 2025 (29d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Nov 18, 2025 (40d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 3, 2025 (28d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 3, 2025 (4d later)Sell$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Sep 12, 2025 (29d later)Sell$1,001 - $15,000
- Val Hoylehouse · OR04 · disclosed Sep 12, 2025 (318d later)Buy$1,001 - $15,000
- Virginia Ann Foxxhouse · NC05 · disclosed Jul 4, 2025 (10d later)Sell$1,001 - $15,000
- Jefferson Shrevehouse · IN06 · disclosed Jun 23, 2025 (42d later)Sell$15,001 - $50,000
- Thomas Hawley Tubervillesenate · AL · disclosed May 15, 2025 (30d later)Sell$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed May 15, 2025 (44d later)Sell$1,001 - $15,000
- Greg Landsmanhouse · OH01 · disclosed Apr 9, 2025 (13d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.